Researchers have claimed that a new artificial heart valve made from the plastic material SEBS is safe to use after they successfully tested the innovative solution for safety for a period of six months.
SEBS polymer artificial heart valve prototype.
(Source: Professor Raimondo Ascione, University of Bristol)
Bristol/UK – The next generation of an artificial heart valve made from a new plastic material could be a step closer to bedside. The research, led by the Universities of Bristol and Cambridge, demonstrated that the polymer material used to make the new artificial heart valve is safe following implant in an animal model for six months.
The study, funded by the British Heart Foundation (BHF) has recently been published in the European Journal of Cardio-Thoracic Surgery.
Currently, patients who need heart valve replacements face trade-offs. Mechanical heart valves are durable but require lifelong blood thinners, while biological (animal tissue) heart valves are more natural but tend to wear out more quickly.
The new kind of artificial heart valve made from a special plastic called SEBS might offer the best of both worlds — but the safety of this new material must be confirmed before they can be tested in humans.
In this new study, researchers tested a research-grade prototype of a new heart valve made entirely from SEBS polymers in a preclinical cardiac surgery model that mimicked how these valves might perform in humans. The team implanted the prototype polymeric artificial heart valve in seven sheep, which was carried out by an independent preclinical facility in Paris, France.
The animals, and their wellbeing, were then monitored over six months, to examine potential long-term safety issues associated with the plastic material such as mineral build up (calcification), material dissolving, blood clots, damage of the heart tissue in contact with the material, cancer, cell death, liver or kidney failure, nutrition and weight and other issues as determined by the regulator.
The research found after six months there was no evidence of harmful calcification (mineral buildup) or material deterioration; blood clotting or signs of cell toxicity. Animal health, wellbeing, blood test results and weight gain overtime were all stable and normal, and the prototype heart valve functioned well throughout the testing period, with no need for blood thinners.
Raimondo Ascione, NHS Adult Cardiac Surgeon, Professor of Cardiac Surgery and Translational Research and Director of the Translational Biomedical Research Centre (TBRC) at the University of Bristol, clinical lead on the project and corresponding author, said: “Currently 1.5 million patients around the world require heart valve replacements every year. More than 35 million patients’ heart valves are permanently damaged by rheumatic fever and with an ageing population this figure is predicted to increase four to five times by 2050.
“Our findings could mark the beginning of a new era in artificial heart valve being made from the new plastic material — one that may offer safer, more durable and more patient-friendly options for patients of all ages, with fewer compromises.”
Geoff Moggridge, Professor of Chemical Engineering Science at the university of Cambridge and biomaterial lead on the project said: “We are pleased that the new plastic material has been shown to be safe after 6 months of testing in-vivo.
“Confirming the safety of the material has been an essential and reassuring step for us, and a green light to progress the new heart valve replacement toward bedside testing.”
The researchers early bench results suggest that their artificial heart valves made from SEBS could feature excellent durability and hemo-compatible i.e. without the need for lifelong blood thinners.
While this is still early-stage research and limitations of the small sample size, the findings are a major hurdle toward future human testing. The next step will be to develop a clinical-grade version of the SEBS polymer heart valve and test it in a larger preclinical trial before seeking approval for a pilot human clinical trial.
Paper: ‘Material safety of styrene-block-ethylene/butylene-block-styrene copolymers used for cardiac valves: 6-month in-vivo results from a juvenile sheep model’ by Raimondo Ascione, Joanna R Stasiak, Daniel Baz-Lopez, Marta Serrani, Geoff Moggridge in the European Journal of Cardio-Thoracic Surgery.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.